What does “ready for manufacturing” actually mean?

A promising ingredient list is only the start. A manufacturer also needs to know which materials to buy, how much of each to use, what the equipment must deliver and how the finished product will be accepted. Leaving those decisions open can produce attractive quotes for products that are materially different.

Use three separate decision points. A budget estimate can work from stated assumptions. A firm manufacturing quote needs a defined scope and explicit exclusions. Production approval needs controlled documents, qualified materials, a suitable process and agreed quality checks. A deposit or purchase order does not resolve missing technical decisions.

This guide focuses on preparing a Canadian natural health product (NHP) for contract manufacturing. The handover structure also helps other supplement projects, but classification, licensing and testing requirements must be checked for each market. It is a planning framework, not a universal specification or a batch-release authorization.

The handover should support each decision in this pathway. Approval to produce and approval to release the finished lot are separate.

1. Fix the product brief before the formula spreadsheet

Write a one-page brief that everyone can price and develop against. Include the intended user, market, claims, dosage form, daily serving, pack count, proposed shelf life, storage conditions and commercial target. Record the product licence status and any unresolved regulatory questions.

• Separate non-negotiable requirements from preferences: a two-capsule serving may be fixed, while capsule colour may be flexible.

• State exclusions and positioning requirements, such as allergens, animal-derived materials, flavour restrictions or a certification you intend to obtain. Confirm evidence and production-site suitability before promising them.

• Give the first-order quantity, annual forecast and delivery destination. Identify whether you need bulk capsules, filled bottles or fully labelled retail packs.

• Record who approves formula, packaging, artwork and costs, with a version number and date on every document.

A proposed claim should be reviewed before dose and format are locked. A formula that physically fits may still be unsuitable for the intended population, market or claim. Likewise, an ingredient appearing in a supplier catalogue does not establish that your finished product can be sold as proposed.

2. Build ingredient specifications a manufacturer can purchase against

A specification describes what a material must meet. A certificate of analysis (COA) reports results for a particular lot. A marketing sheet describes the product. Keep those roles separate, and compare the supplier’s proposed material with your requirements rather than accepting the ingredient name as sufficient.

Include these fields for each ingredient

• Identity and grade: precise material name, chemical form or biological source, internal material code and any applicable standard.

• For a botanical: species, plant part, extract ratio where relevant, extraction solvent, carrier content and specified marker or active constituent.

• Composition and strength: assay range and units; whether results are on an as-is or dry basis; elemental contribution for minerals; declared carriers and processing aids.

• Physical properties relevant to the process: particle-size range, bulk and tapped density, moisture or water activity where useful, flow behaviour and appearance.

• Quality limits and methods: appropriate identity, assay and microbial tests, plus chemical-contaminant controls selected for the material and its risks.

• Supply and handling: manufacturer and supplier, storage requirements, expiry or retest date, transport restrictions, allergen information and traceability documents.

For example, “botanical extract, 200 mg” leaves important questions open. A usable entry identifies the actual extract and carrier system, the assay basis and the material specification revision. Changing any of those may alter fill volume, taste, testing, cost or the regulatory assessment.

The manufacturer may help write or qualify these specifications. Agree who approves them and who approves alternative suppliers. A second source is useful only after its material has been assessed for the intended formula and process.

Source: Health Canada: Quality of Natural Health Products Guide

3. Reconcile label amounts, raw-material inputs and excipients

Your master formula should show each material’s actual input per dosage unit, the contribution to the intended declaration, units per serving and the resulting daily amount. Include every excipient and the capsule shell or other dosage-form components. Specify the calculation basis so milligrams, micrograms, percentages and activity units cannot be confused.

A simple potency calculation

In a hypothetical calculation, supplying 40 mg of a measured constituent from a powder assayed at 20% requires 40 ÷ 0.20 = 200 mg of that powder. The remaining 160 mg still occupies space. This is arithmetic, not a recommended ingredient or dose; it does not determine how the material should be declared on a Canadian label.

If the supplier assay is reported on a dry basis, confirm the appropriate moisture correction before treating it as an as-is manufacturing input. For minerals, distinguish the compound’s weight from its elemental contribution. For enzymes and probiotics, reconcile activity or viable-count units with the raw material’s strength and the intended finished-product requirement.

Keep three concepts separate: assay correction adjusts input for measured raw-material strength; a justified formulation overage addresses a defined loss or stability need; manufacturing yield allowance accounts for material and units lost during processing. An arbitrary extra percentage is not a substitute for controlling the process.

Do not leave excipients as an unspecified remainder

Identify proposed fillers, glidants, lubricants, binders, flavours, sweeteners and other processing materials with their functions and permitted adjustment ranges. Have changes reviewed for performance, ingredient suitability, label impact and any licence implications. “The manufacturer will add what it needs” is too open-ended for a controlled handover.

4. Calculate capsule fill using volume and measured density

There is no universal “500 mg capsule.” Capsule size describes a volume, while fill weight depends on the blend and filling process. Bulk and tapped density are useful development measurements; neither should be treated as proof of the density achievable on the chosen encapsulator. Confirm the blend, shell and equipment together.

Worked example: will a 450 mg blend fit?

Assume an illustrative fill of 300 mg of material A, 100 mg of material B and 50 mg of excipients per capsule: 450 mg total powder. The shell weight is additional and is not part of that fill target. These are fictional materials for calculation only.

For the initial screen, assume a measured blend density of 0.55 g/mL. Use the selected supplier’s capacity chart: the cited Torpac hard-gelatin chart lists a theoretical body volume of 0.68 mL for size 0 and 0.95 mL for size 00. Other shell designs and suppliers can differ.

• Estimated fill mass = capsule volume × assumed fill density × 1,000.

• Size 0: 0.68 × 0.55 × 1,000 = 374 mg. The 450 mg target exceeds this screening estimate.

• Size 00: 0.95 × 0.55 × 1,000 = 522.5 mg. The target appears feasible on volume, subject to a filling trial.

• Required volume: 0.450 g ÷ 0.55 g/mL = approximately 0.818 mL.

• Sensitivity check: at 0.45 g/mL, that size 00 estimate falls to 427.5 mg, below the target.

Do not specify a universal spare-capacity percentage. Check fill consistency, shell closure, powder retention and performance at a realistic speed. If the formula does not fit, reassess excipients, material properties, capsule size, units per serving or dosage form without casually reducing the intended dose.

Source for the example capsule volumes and filling limitations: Torpac capsule specifications.

Translate the unit formula into a batch

At 60 capsules per bottle, an order for 10,000 bottles requires 600,000 saleable capsules. At 450 mg fill each, that is 270 kg of powder in saleable units: 180 kg of material A, 60 kg of material B and 30 kg of excipients in this simplified example.

Those figures exclude development trials, rejected units, line losses, laboratory samples and retained samples. Ask the manufacturer to state its planned batch charge and expected yield separately. If the serving is two capsules, each bottle provides 30 servings; the label and cost-per-day comparison should use that same basis.

5. Prepare a sample manufacturer handover package

Use the following nine-part package as a starting structure. The filenames are suggested document labels you can adapt. At quotation stage, identify open assumptions; before production, replace them with approved decisions. Mark every document with the same product code, revision, owner and approval status.

01 — Product brief

Include market, licence status, intended claims and population, dosage form, serving, pack count, initial order, forecast, target delivery date, commercial constraints and decision owners. Example: Product PP-01, 60 capsules per bottle, two-capsule serving, 10,000-bottle quotation, Canada; capsule material and packaging to be confirmed. This is a sample brief, not an approved product.

02 — Formula and bill of materials

Supply an editable calculation sheet plus a controlled reference copy. Include material codes, exact descriptions, actual input per capsule, contribution per serving, assay basis, excipients, shell, proposed batch quantities and calculation checks. Record any authorized overage separately with its rationale. State which changes require prior approval.

03 — Ingredient and supplier dossier

Attach proposed raw-material specifications, representative COAs, relevant technical data and supporting declarations. Identify the approved or proposed source for each material and any supply risks. A representative COA helps assessment; actual production lots still require their own acceptance process.

04 — Finished-product specification and testing plan

List the intended tests, methods or method references, acceptance criteria, sampling stages, laboratory, sample quantities and owner. Clearly identify method-development work still required, tests included in the manufacturing quote and any additional retailer or marketplace requirements.

05 — Process-transfer and pilot brief

Describe prior development work, trial batches, observed problems and proposed mixing or processing sequence. Identify sensitive ingredients and critical questions for the pilot. Let the manufacturer translate the transfer brief into its controlled, equipment-specific manufacturing instructions.

06 — Packaging specification and artwork

Define bottle or pouch material, size, closure, liner or seal, desiccant if applicable, unit count, label dimensions, carton and shipping configuration. Supply artwork status, coding requirements and approved proofs when available. State whether the manufacturer sources components or receives customer-supplied stock.

07 — Stability and storage plan

State the proposed shelf life, available supporting data, intended commercial pack, storage conditions, study responsibilities and reporting schedule. Identify which decisions remain provisional and what evidence is needed to support the assigned expiry.

08 — Quality responsibilities and change control

Set out responsibilities for material approval, testing, deviations, out-of-specification investigations, release, records, retained samples, complaints and recalls. Define approval of substitutions and changes. Record formula ownership, confidentiality and access to technical records in the appropriate agreements.

09 — Quote sheet and decision log

Request the same quantity tiers, pack configuration and scope from each manufacturer. Include a checklist of assumptions and exclusions, outstanding questions, quotation validity, payment terms and the trigger for each lead-time estimate. Log every agreed revision so an old spreadsheet does not become the manufacturing instruction.

This brand-side package supports the manufacturer’s master production document and batch records; it does not replace them. Health Canada’s operations guidance distinguishes the controlled production instructions from the records documenting what actually occurred for a batch.

Source: Health Canada GUI-0158, sections 48–50: operations and batch records

6. Design the pilot batch to answer specific questions

A good pilot has a written purpose, predefined checks and a documented conclusion. Choose scale and equipment because they address transfer risks, not because a small run is cheap. Explain differences from the intended commercial process and decide what further scale-up work is required.

Before the pilot

• Approve the trial formula and material lots. Record actual assay, density and other relevant material characteristics.

• Define the equipment, batch size, mixing sequence, hold conditions and sampling plan. Decide which observations could stop the trial.

• Agree acceptance criteria and how failures will be investigated. Product-specific limits should be justified; do not copy a convenient universal tolerance.

During the pilot

• Assess dispensing and mixing: transfer losses, dust, clumping, mixing behaviour and risk of separation during discharge or hopper feeding.

• Check blend uniformity with an appropriate, justified sampling and analytical approach. Similar capsule weights alone do not establish even distribution of every ingredient.

• For capsules, monitor net fill weight over the run, closure, damaged shells, leakage, rejects and stable operating speed.

• For tablets, assess compression behaviour, weight, physical integrity and relevant performance tests. For gummies or liquids, include process temperature, pH, settling or texture where relevant.

• Record actual settings, interventions, downtime, yield and unexpected observations. Preserve enough information to explain a successful or unsuccessful run.

After the pilot

• Review agreed analytical, microbiological and physical results alongside process records; visual appearance is only one check.

• Run the proposed product through its pack where practical: count accuracy, seal or closure, coding, label fit and transport handling.

• Document changes, remaining risks and the next trial or scale-up step. Decide whether the formula, process and pack are ready to lock.

• Identify samples for stability and other follow-up work. Record whether pilot data represent the commercial product and where that equivalence remains unproven.

A successful pilot supports a production decision. It does not by itself establish shelf life, clinical effectiveness, regulatory authorization or continuing performance at commercial scale.

7. Agree testing, packaging and shelf-life responsibilities

For a Canadian NHP, section 44 requires specifications covering purity, medicinal-ingredient identity and quantity per dosage unit, potency where represented, and testing or examination methods. Specifications and changes require approval by a quality assurance person (QAP).

Source: Natural Health Products Regulations, section 44: specifications

Build a practical testing matrix: attribute → method → acceptance criterion → sampling stage → laboratory → decision owner. Cover material acceptance, in-process checks, finished-product release and stability. Confirm sample needs and method suitability before booking a production date.

Do not assume that every raw-material COA replaces finished-product testing. Health Canada permits certain approaches such as quantification by input under defined conditions, with supporting specifications, records and process controls. The appropriate testing strategy needs a documented product-specific assessment.

Source: Health Canada GUI-0158, sections 43–47: specifications and testing

For packaging, check the complete container-and-closure system rather than choosing from appearance alone. Consider moisture and oxygen protection, light exposure, seal integrity and compatibility with the product and line. Identify the final packaging revision in the stability plan.

A proposed shelf life is a development target until supported by suitable evidence. Agree the basis for the initial expiry and the ongoing real-time program, including the commercial formulation and packaging or a scientifically justified equivalent. Do not let a standard date in a quote become the shelf-life rationale.

Source: Health Canada GUI-0158, sections 52–62: stability and records

Plan the study in detail: Supplement Stability Testing — Shelf Life, Packaging and Formulation.

8. Send the documents needed for an accurate manufacturing quote

You can request an early budget before every technical question is closed. Ask the supplier to label it as an estimate and list the assumptions. For comparable, decision-ready quotes, send the same versioned package to each manufacturer and request a line-by-line scope.

• Product: formula revision, specifications, dosage form, shell or flavour, units per serving and units per pack.

• Quantity: order sizes to price, forecast, minimum order basis and whether minimums apply to bulk material, finished units, packaging or a particular SKU.

• Supply: manufacturer-sourced versus customer-supplied materials, approved brands or grades, and treatment of unused ingredients and packaging.

• Development: feasibility work, samples, pilot runs, method work, tooling and setup charges.

• Quality: included tests, external laboratory charges, release documentation, stability pulls and retained samples.

• Packaging: components, printing, artwork checks, line setup, coding and shipping cartons.

• Commercial terms: unit price basis, currency, taxes, freight, delivery location, payment terms, quote validity, lead-time assumptions and yield or quantity tolerances.

Compare cost per saleable bottle and per daily serving, with one-time charges shown separately. A price that excludes testing, packaging components or development work cannot be compared directly with a fully scoped price. Confirm how substitutions, failed trials, retesting and customer-driven changes will be quoted.

A short request you can adapt

“Please quote the attached PP-01 package at revision 1 for 10,000 bottles of 60 capsules. Identify assumptions and deviations from the requested materials, formula, tests and packaging. Separate recurring unit costs from development, pilot, tooling, testing and stability charges. State the minimum order, expected saleable yield, quotation validity and when the lead time begins. Please obtain written approval before making substitutions.”

This is an illustrative request, not a representation of Kompete’s pricing, order minimums or lead times.

9. Close the production decision with a written readiness review

Before authorizing the commercial batch, review the approved formula, specifications, current manufacturing instructions, pilot findings, packaging, artwork, material availability and testing arrangements together. Assign an owner and due date to each open item. A critical unresolved item should result in a hold or an explicitly limited development run, not an assumed approval.

Distinguish authorization to manufacture from authorization to release for sale. For Canadian NHPs, materials, procedures and the finished lot have relevant QAP approval requirements. A commercial deadline does not replace that quality decision.

Source: Health Canada GUI-0158, section 51: quality assurance and release

Avoid silent changes after sign-off. A new supplier, different extract carrier, capsule material, processing condition or pack may require technical and regulatory assessment, updated costs, additional trials or stability work. Keep the reason, impact assessment and approval with the controlled revision.

How Kompete can help prepare your formula for production

Start with the documents you already have: formula spreadsheet, proposed claims, supplier specifications or COAs, packaging concept and any manufacturer quote. Kompete can scope a review of formulation feasibility, technical gaps, testing needs and the information required for manufacturer discussions.

The useful output is a clearer decision: what is ready, what must be resolved and what the manufacturer needs next. The manufacturer and its quality team remain responsible for their controlled production procedures and release decisions.

Request a pre-production formula review.

Related practical guides

Supplement stability testing: plan shelf life and packaging studies.

Canadian NHP labelling: what to check before printing.

Choosing an NHP contract manufacturer: GMP questions before you sign.

Reviewed 28 October 2026. The package, calculations and pilot suggestions are illustrative planning tools. Final limits and decisions depend on the product, process, target market and qualified quality review.